EUVIMED · CrossrefZeitschrift
Oncology & Haematology
ISSN 2752-5481 · Touch Medical Media, Ltd.
Neueste Artikel
Imipridones in Diffuse Midline Gliomas: A Review of the Timeline from Drug Discovery to Dopamine Receptor D2 and Caseinolytic Protease P (ClpP) Target Identification and the Trials Leading to FDA Approval
Skin Cancers and Acquired Immunosuppression: Epidemiology and Emerging Management Strategies
What are the Latest Advances in Pancreatic Cancer Care?
Targeting HER2 in advanced non-small cell lung cancer: The emerging role of zongertinib
Contemporary management of gastrointestinal cancers: Advances in targeted therapy, immunotherapy and biomarkers
Frontline treatment for diffuse large B-cell lymphoma in 2026: Lessons from targeted and immune-based approaches
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR -mutated Non-small Cell Lung Cancer
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer
Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances
High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy
New Approaches to Allogeneic Haematopoietic Cell Transplantation
Criteria for Evaluating Multi-cancer Early Detection Tests
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib
Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma
COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia: What Can We Expect?
Implementing the European Code of Cancer Practice to Improve Europe’s Cancer Outcomes
Melphalan Flufenamide: a Peptide-Drug Conjugate for the Treatment of Multiple Myeloma
New and Emerging Therapeutics for Non-metastatic Castrate-resistant Prostate Cancer
Haplo-identical Haematopoietic Stem Cell Transplantation in Refractory Hodgkin Lymphoma After Carmustine, Etoposide, Cytarabine, Melphalan Conditioning Regimen
The Future of Advanced Prostate Cancer Treatment
Lymphocyte-activation Gene 3 and Programmed Cell Death 1 Checkpoint Inhibition as a Novel Combination in Advanced Melanoma
A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives
Bruton's Tyrosine Kinase Inhibitors for the Treatment of Waldenström's Macroglobulinaemia: A Canadian Perspective
Daratumumab for Immunoglobulin Light Chain Amyloidosis
Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria
New Checkpoint Inhibitors and Immunotherapies for Solid Tumours
The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine
Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers
Pembrolizumab and Chemotherapy in Cervical Cancer: A New Standard of Care?
EUVIMED